Peptides›Other›Teriparatide

Teriparatide

/ Recombinant human parathyroid hormone amino acids 1-34

TIER 1 · ClinicalN = 0 · TESTING PENDINGLAST REVIEW 2026·04·20

ALIAS · Forteo · rhPTH(1-34)

—

Pass rate

Samples

Suppliers

Research use onlyAny dose figures below describe what specific cited studies used, reported factually. Nothing on this page is guidance for human use.READ FIRST →

Terms in this page you can click for a plain-English popup: , , , , , , , .

§ A · Identity

Primary sequence— sequence not captured —

MW · —CLASS · Recombinant human parathyroid hormone amino acids 1-34CATEGORY · Other

FDA-approved (Forteo, 2002) for osteoporosis in postmenopausal women and men at high fracture risk. Only PTH analog approved for bone-building (anabolic) therapy.

§ B · Mechanism of action

Teriparatide is recombinant human parathyroid hormone comprising the N-terminal 34 amino acids (rhPTH 1-34). Unlike chronic elevation of PTH (which causes bone resorption), intermittent daily PTH administration produces a net anabolic effect on bone, stimulating osteoblast activity and increasing trabecular and cortical bone formation.

§ C · Human clinical evidence

Pivotal fracture trials in postmenopausal women (Neer 2001, NEJM) demonstrated reduction in vertebral and nonvertebral fractures. Approved indications include osteoporosis in postmenopausal women, osteoporosis in men, and glucocorticoid-induced osteoporosis.

§ D · Primary literature

PubMed11346808Neer RM et al. — Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis · The New England Journal of Medicine · human-phase-3-rctDaily PTH(1-34) for median 21 months reduced new vertebral fracture risk by 65% and non-vertebral fractures by 53% versus placebo in postmenopausal osteoporosis.Limitations: Stopped early due to rat osteosarcoma signal; full lifetime exposure not characterised.2001

§ F · Safety signal

Boxed warning: rodent studies showed dose- and duration-dependent osteosarcoma. Original labeling limited treatment duration to 2 years; the restriction was removed in 2020 after long-term human data did not replicate the rodent malignancy signal. Other AEs include hypercalcemia, nausea, orthostatic hypotension.

§ H · Regulatory status

Regulatory status

FDA status:: FDA-approved
Compounding:: Not eligible for compounding (approved, not in shortage)